 |
 |
PDC Biotech GmbH is a biotechnology company developing novel compounds for the treatment of preterm labour and primary dysmenorrhea. At the core of the company is our unique, proprietary series of prostaglandin F2α (FP) receptor antagonists. Preterm labour and primary dysmenorrhea are areas of significant unmet medical need. Excessive uterine contractility in both conditions is mediated by PGF2α.
PDC's initial goal is to progress the company's lead compound, PDC31 to the clinical stage by 2010 and establish proof-of-concept of the ability of the compound to inhibit uterine contractions in non-pregnant women.
More about us
Recent news:
October 30, 2009 PDC Biotech GmbH Announces Close of Series A Financing
|
|
